Topics

Postplacental Insertion of Levonorgestrel-releasing Intrauterine System (LNG-IUS) After Cesarean vs. Interval Insertion

2014-08-27 03:32:12 | BioPortfolio

Summary

The study is a randomized controlled trial comparing outcomes of immediate postplacental insertion of the levonorgestrel-releasing intrauterine system (LNG-IUS) vs. interval insertion of the LNG-IUS performed 4-8 weeks after delivery for patients undergoing scheduled cesarean delivery.

Our primary hypothesis is that the proportion of women using the LNG-IUS for contraception at 12 months after delivery will be higher in the group randomized to immediate post-placental insertion.

Study Design

Allocation: Randomized, Control: Active Control, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment

Conditions

Healthy

Intervention

Levonorgestrel-releasing intrauterine system (LNG-IUS), Levonorgestrel-releasing intrauterine system (LNG-IUS)

Location

University of Chicago
Chicago
Illinois
United States
60637

Status

Active, not recruiting

Source

University of Chicago

Results (where available)

View Results

Links

Published on BioPortfolio: 2014-08-27T03:32:12-0400

Clinical Trials [4181 Associated Clinical Trials listed on BioPortfolio]

Clinical Trial the Use of Levonorgestrel-releasing Intrauterine System Versus Etonogestrel Implant in Endometriosis

Randomized clinical trial the use of levonorgestrel releasing intrauterine system. Objectives: To evaluate and compare the efficacy of- levonorgestrel releasing intrauterine system l(LNG-...

The Use of Levonorgestrel-Releasing Device (Metraplant-E) in the Treatment of Dysfunctional Uterine Bleeding

Research hypothesis: Release of levonorgestrel from Metraplant-E levonorgestrel releasing intrauterine contraceptive device is inadequate to be used as a medical line of treatment of dys...

Comparison of Estrogen-progestin Therapy in Continuous Regimen Versus Combination Estrogen-progestin Therapy in Continuous Regimen Plus Levonorgestrel-releasing Intrauterine System (LNG-IUS)

Adenomyosis is characterized by the appearance of endometrial cells in the muscular layer of the uterus. It affects about 15-20% of the female population. The symptoms of adenomyosis are ...

A Study of a Levonorgestrel-Releasing Intrauterine System for Long-Term, Reversible Contraception

The primary objective of this study is to assess the efficacy of a levonorgestrel-releasing intrauterine system (LNG20) in nulliparous and parous females of child-bearing potential who req...

Levonorgestrel-releasing Intrauterine System Versus a Low-dose Combined Oral Contraceptive for Management of Adenomyosis Uteri

This study aims to compare the efficacy of LNG - IUD (Levonorgestrel releasing intrauterine device) Versus Low dose COCs (combined oral contraceptive pills) on management of heavy menstrua...

PubMed Articles [16826 Associated PubMed Articles listed on BioPortfolio]

Treatment of symptomatic adenomyosis with the levonorgestrel-releasing intrauterine system.

To determine the long-term effects of using the levonorgestrel-releasing intrauterine system (LNG-IUS) to treat symptomatic adenomyosis.

Tamoxifen for the prevention of unscheduled bleeding in new users of the Levonorgestrel 52mg intrauterine system: a randomized controlled trial.

To determine if a course of oral tamoxifen initiated following placement of a levonorgestrel 52mg intrauterine system (IUS) reduces bleeding/spotting days over 30days.

Levonorgestrel intrauterine contraceptive systems (13.5 mg and 52 mg) and risk of ectopic pregnancy.

The objective was to investigate the Pearl index for ectopic pregnancy in women using levonorgestrel intrauterine system (LNG-IUS) at time of conception.

Case report of the successful use of Mirena levonorgestrel intrauterine system in a patient with didelphys uterus and obstructed hemivagina.

The Mirena levonorgestrel intrauterine system (IUS) is frequently used for menstrual suppression in adolescents with special needs. However, the presence of a uterine anomaly is generally considered a...

Corrigendum. Mifepristone treatment prior to insertion of a levonorgestrel releasing intrauterine system for improved bleeding control - a randomized controlled trial.

Medical and Biotech [MESH] Definitions

Spontaneous loss of INTRAUTERINE DEVICES from the UTERUS.

Cell surface proteins that bind corticotropin-releasing hormone with high affinity and trigger intracellular changes which influence the behavior of cells. The corticotropin releasing-hormone receptors on anterior pituitary cells mediate the stimulation of corticotropin release by hypothalamic corticotropin releasing factor. The physiological consequence of activating corticotropin-releasing hormone receptors on central neurons is not well understood.

The shifting in position or location of an INTRAUTERINE DEVICE from its original placement.

Intrauterine devices that release contraceptive agents.

Intrauterine contraceptive devices that depend on the release of metallic copper.

More From BioPortfolio on "Postplacental Insertion of Levonorgestrel-releasing Intrauterine System (LNG-IUS) After Cesarean vs. Interval Insertion"

Quick Search

Relevant Topics

Women's Health
Women's Health - key topics include breast cancer, pregnancy, menopause, stroke Follow and track Women's Health News on BioPortfolio: Women's Health News RSS Women'...

Nutrition
Within medicine, nutrition (the study of food and the effect of its components on the body) has many different roles. Appropriate nutrition can help prevent certain diseases, or treat others. In critically ill patients, artificial feeding by tubes need t...


Searches Linking to this Trial